Insulet eyes Middle East expansion as McEvoy talks future plans

Insulet (Nasdaq:PODD) has its eyes on future expansion in new geographies, according to some of its leading executives.

Speaking during the Wells Fargo Conference last week (transcribed by Investing.com), President and CEO Ashley McEvoy and EVP and CFO Ana Maria Chadwick outlined expansion plans for its automated insulin delivery technology, particularly in the Middle East.

“We see durable growth in international,” Chadwick said. “We’re launching in the Middle East in the early part of 2026 and we have layers of growth.”

McEvoy cited a lot of opportunities in the Middle East, particularly in Saudi Arabia. Beyond that, Asia could enter the mix for Insulet — one of the largest diabetes tech companies in the world — but McEvoy said the company will provide a wider view into its geographic expansion plans during an investor day event on Nov. 20.

Read more about Insulet and the rest of the diabetes tech industry in our free Diabetes Technology Special Report.

Elsewhere, the company already has the wheels in motion on international expansion for its Omnipod 5 system. At the start of this year, Insulet began rolling out the system in Italy, Denmark, Finland, Norway and Sweden. Those expansions followed launches of Omnipod 5 in the U.K., Germany, Netherlands, and France. Insulet also launched the system in Canada earlier this year.

“Our larger markets continue to be, of course, U.K., Germany, and France,” Chadwick said. “They’re large. They continue to grow.”

Meanwhile, the company aims to continue leading in the U.S. in the type 1 diabetes category while expanding its reach domestically and abroad.

“Our strategy remains intact in that we’re going to lead with type 1 in the U.S.,” McEvoy said. “We’re also going to take advantage of our first mover advantage in the U.S. with type 2. We’re going to continue in a very thoughtful, strategic way of geographic expansion, and we’re going to continue to invest in platform innovation as well as building out capacity to say yes to future growth.”

More about future plans at Insulet

McEvoy, who took over the corner office in April, said the company’s upcoming priorities include getting the Omnipod 5 connected to the latest-generation sensors. She also noted smartphone control capabilities in Europe, too.

Notably, the company has clinical trials underway on next-generation algorithms, called Strive and Evolution. One involves SmartAdjust 2.0, the next algorithm update for the Omnipod 5. The other evaluates a fully closed-loop algorithm for the type 2 population.

(SVP and Chief Medical Officer, Dr. Trang Ly, spoke to Drug Delivery Business News  about what’s to come at Insulet at the American Diabetes Association’s 85th Scientific Sessions in Chicago in June.)

“People don’t want more knobs to turn,” Ly said at the time. “They want more automation. They want to forget about their diabetes. So, we’re delivering that through more automation. … But, we haven’t announced any timing for that. We’re going to get into clinical, and we’ve got to see whether it works or not.”

For the future in terms of strategy, McEvoy said she wants to challenge Insulet on more agile innovation as it seeks more share. She said the company aims to invest in market development, demand generation and brand management to make people more aware of Omnipod everywhere.

“We have big ambition for the future,” McEvoy said. “While our strategies are intact, you’re going to see us also evolve from the mindset we were born out of to be the disruptor to be the market leader. We now are the market leader. … You’re going to see us invest more in innovation.”